Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2021-04-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯-关于使用部分暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of temporarily idle funds for cash management, including details about the amount, duration, types of financial products, risk controls, and approvals by the board and independent directors. It includes financial data to support the announcement but does not contain comprehensive financial statements or detailed financial performance analysis. The document is a formal disclosure about a financing activity related to cash management and investment of idle funds, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and is a detailed announcement, not just a brief notice or a report publication announcement.
2021-04-28 Chinese
普莱柯-独立董事2020年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors 2020 Annual Report" and contains detailed information about the independent directors' qualifications, attendance at board and shareholder meetings, opinions on various company matters, oversight activities, and evaluations of company governance and internal controls for the year 2020. It is a comprehensive report on the independent directors' annual duties and observations rather than a general annual report or financial statement. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). The content focuses on board/management oversight and director activities, which aligns best with Board/Management Information (MANG).
2021-04-28 Chinese
普莱柯2020年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2020 Annual Report Summary" of Pulike Bioengineering Co., Ltd. It contains detailed financial data for the year 2020, including main accounting data, quarterly financial figures, shareholder information, business overview, and management discussion. The presence of audited financial data, profit distribution plans, and comprehensive company information aligns with the characteristics of an official yearly report covering company activity and full financial performance. The document length is over 6,000 characters, indicating it is the report itself rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-28 Chinese
普莱柯关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's articles of association (公司章程). It details specific amendments to the articles, including provisions about share repurchases, director responsibilities, and shareholder voting rights. The document states that the amendments will be submitted to the shareholders' meeting for approval and authorizes management to handle related registration matters. The content is regulatory and governance-related, focusing on internal company rules rather than financial results or meeting materials. The document length is relatively short (2493 characters), and it is a formal announcement of changes to governance documents rather than the governance report itself. Therefore, the most appropriate classification is Governance Information (CGR).
2021-04-28 Chinese
普莱柯审计委员会2020年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Audit Committee 2020 Annual Performance Report" of 普莱柯生物工程股份有限公司. It details the audit committee's activities, including oversight of external auditors, review of financial reports for 2019 and quarterly reports in 2020, internal audit supervision, and internal control evaluation. The document is a report from the audit committee to the board summarizing their work and findings for the year 2020. It is not the full annual report or financial statements but a standalone report focused on audit committee activities and audit oversight. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related information. The document length is 2740 characters, which is consistent with a detailed committee report rather than a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-28 Chinese
普莱柯2020年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2020年度监事会工作报告" which translates to "2020 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of financial reports, internal controls, related party transactions, and plans for 2021. The content focuses on the supervisory board's review and oversight functions rather than presenting full financial statements or comprehensive annual financial performance. The document length is 3187 characters, which is relatively short and more consistent with a report on supervisory activities rather than a full Annual Report (10-K) or Interim Report (IR). It is not an announcement or publication notice but a substantive report on supervisory board work. This type of document aligns best with the Audit Report / Information (AR) category, which includes reports on audit results, internal controls, and supervisory board activities, excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2020
2021-04-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.